Ofatumumab

Common brands: Kesimpta, Vitamin D, Neurontin, Gralise, Gaba 300-Ezs

Top reporter: Novartis Pharmaceuticals Corporation

CD20-directed Cytolytic Antibody [EPC]Provitamin D2 Compound [EPC]Corticosteroid [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Alkylating Drug [EPC]
32,441
Total Reports
28,553
Serious Reports
750
Death Reports
30
Reported Reactions
Death Report Ratio: Moderate (2.31%)

Patient Demographics

Male
7,505
Female
21,805

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Ofatumumab.

# Reaction Reports % of Total
1 FATIGUE 5,478
10.5%
2 HEADACHE 4,593
8.8%
3 PYREXIA 3,534
6.8%
4 PAIN 3,524
6.8%
5 CHILLS 3,459
6.6%
6 INFLUENZA LIKE ILLNESS 2,850
5.5%
7 NAUSEA 1,791
3.4%
8 MULTIPLE SCLEROSIS RELAPSE 1,661
3.2%
9 COVID-19 1,515
2.9%
10 ASTHENIA 1,477
2.8%
11 MULTIPLE SCLEROSIS 1,439
2.8%
12 GAIT DISTURBANCE 1,414
2.7%
13 HYPOAESTHESIA 1,379
2.7%
14 FEELING ABNORMAL 1,345
2.6%
15 MALAISE 1,340
2.6%
16 DIZZINESS 1,298
2.5%
17 NASOPHARYNGITIS 1,241
2.4%
18 DRUG INEFFECTIVE 1,215
2.3%
19 PAIN IN EXTREMITY 1,158
2.2%
20 INJECTION SITE PAIN 1,008
1.9%
21 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 980
1.9%
22 COUGH 979
1.9%
23 FALL 972
1.9%
24 ARTHRALGIA 965
1.9%
25 URINARY TRACT INFECTION 948
1.8%
26 ACCIDENTAL EXPOSURE TO PRODUCT 915
1.8%
27 VOMITING 909
1.7%
28 BACK PAIN 899
1.7%
29 MYALGIA 889
1.7%
30 MUSCULAR WEAKNESS 862
1.7%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.